Melanie Beal
Family · Kansas City, KSNPI 1134451453
Payments from drug & device makers
Across 123 payments — averaging $17.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Otsuka America Pharmaceutical, Inc.$361
- AbbVie$230
- Teva Pharmaceuticals USA, Inc.$219
- Novo Nordisk$202
- Vanda Pharmaceuticals Inc.$200
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$163
- plus $801 from 13 others
What the payments were for
- Food & beverage$2,177100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 19 | $361 |
| AbbVie | 10 | $230 |
| Teva Pharmaceuticals USA, Inc. | 14 | $219 |
| Novo Nordisk | 11 | $202 |
| Vanda Pharmaceuticals Inc. | 7 | $200 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 14 | $163 |
| Lilly USA, LLC | 10 | $155 |
| AstraZeneca | 8 | $152 |
| Axsome Therapeutics, Inc. | 8 | $134 |
| Pfizer | 7 | $116 |
| E.r. Squibb & Sons, L.L.C. | 4 | $60 |
| Amgen | 3 | $43 |
| Exact Sciences | 2 | $30 |
| Dexcom, Inc. | 1 | $24 |
| Neurocrine Biosciences, Inc. | 1 | $19 |
| Biohaven Pharmaceuticals, Inc. | 1 | $19 |
| Sumitomo Pharma America, Inc. | 1 | $19 |
| Lundbeck LLC | 1 | $18 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $13 |
How this compares
$2,177 in reported general payments places this provider in the 85th percentile of 1,579 family providers in Kansas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 75 | $81,965 |
| JardianceEmpagliflozin | 68 | $65,947 |
| MounjaroTirzepatide | 20 | $36,932 |
| EliquisApixaban | 24 | $24,232 |
| Spiriva HandihalerTiotropium Bromide | 18 | $15,588 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $10,541 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 16 | $10,206 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 20 | $9,139 |
| TrulicityDulaglutide | 11 | $9,130 |
| JanuviaSitagliptin Phosphate | 11 | $8,564 |
| Lurasidone Hcl | 12 | $5,398 |
| SymbicortBudesonide/Formoterol Fumarate | 11 | $4,896 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 12 | $4,417 |
| Arnuity ElliptaFluticasone Furoate | 19 | $3,940 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 138 | $3,587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $202 | $81,96575 claims |
| Lilly USA, LLCMounjaro, Trulicity | $155 | $46,06231 claims |
| PfizerEliquis | $116 | $24,23224 claims |
| AstraZenecaSymbicort | $152 | $4,89611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,579 family providers in Kansas.
Other family in Kansas City
- Zohra HussainiKansas City$329K
- Adam CaseKansas City$34K
- Kristina DelaneyKansas City$27K
- Amanda WilliamsKansas City$20K
- Mindy EldridgeKansas City$12K
- Liza RodriguezKansas City$11K
- Jhunne GalimbaKansas City$6K
- Graceann SandriKansas City$6K
- Jennifer ChesterOverland Park$327K
- Amanda CaldwellLeawood$203K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.